AVAna Victoria Villar

Ana Victoria Villar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Victoria Villar has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Protein‐Engineered Iron Nanoclusters as Hybrid Theranostic Materials for MRI Monitoring and Treatment of Cardiac Fibrosis

    by Lydia Martínez‐Parra, Andrea García‐Esnaola, Helena Soto, Gabriela Guedes, Lourdes Marcano, Diana H. Panchuelo, Irantzu Llarena, Ana V. Villar, Aitziber L. Cortajarena

    Integrating diagnostic imaging and therapy within a single platform remains a major challenge in precision medicine. Existing approaches mainly rely on multi‐component nanoparticles, increasing formulation complexity and limiting modularity. However, versatile platforms combining imaging and therapeutic functionalities remain limited. Here, we present protein‐engineered iron nanoclusters (Prot‐FeNCs) as hybrid protein‐based systems combining Hsp90‐targeted antifibrotic activity with high‐performance T 1 ‐weighted Magnetic Resonance Imaging (MRI) contrast. Using engineered proteins displaying cysteine‐based coordination sites, we develop a green aqueous synthesis route to ultrasmall iron nanoclusters that provide strong positive T 1 MRI contrast, comparable to gadolinium‐based agents in a biocompatible iron‐based system. Physicochemical characterization confirms metal coordination and structural and functional integrity of the protein scaffold, supporting its use as a template for hybrid materials fabrication. Prot‐FeNCs exhibit minimal iron release, robust stability, low cytotoxicity, and efficient cellular uptake, enabling sustained T 1 contrast in vitro. In a physiologically relevant 3D human engineered cardiac connective tissue model, Prot‐FeNCs selectively accumulate in fibrotic regions, downregulate fibrotic markers, and attenuate tissue remodeling while preserving biomechanical properties and enable reliable MRI‐based quantification of fibrosis severity. Our results position engineered Prot‐FeNCs as a promising modular hybrid theranostic platform whose scalable synthesis, tunable design, and biocompatibility support translation into next‐generation protein‐based nanomedicines.

  • Open Access

    Cardiac fibrosis inhibitor CTPR390 prevents structural and morphological changes in human engineered cardiac connective tissue

    by David Maestro, Ana Palanca, Helena Soto, I. Llarena, Alisa Nicole DeGrave, Gabriela Guedes, Guilherme Henrique de Oliveira, André Luiz Coelho Conceição, Verónica Mieites, Jose M. Icardo, et al.


  • Open Access

    Cardiac fibrosis inhibitor CTPR390 prevents structural and morphological changes in collagen and fibroblasts of engineered human connective tissue

    by David Maestro, Ana Palanca, Helena Soto, I Llarena, Alisa Nicole DeGrave, Gabriela Guedes, Guilherme Henrique de Oliveira, André Luiz Coelho Conceição, Verónica Mieites, Jose M. Icardo, et al.

    Cardiac fibrosis is a key characteristic of heart failure, with no effective treatment available. Using three-dimensional human models and cutting-edge biotechnology to evaluate new therapies offers a significant advancement. CTPR390, an experimental anti-fibrotic inhibitor targeting Hsp90, has shown success in animal models, but remains unexplored in human cardiac models. This study evaluated a cardiac three-dimensional engineered connective tissue (ECT) model treated with CTPR390, focusing on changes in the extracellular matrix and fibroblasts. Results showed that CTPR390 prevented architectural changes in TGFβ1-activated ECT, preserving tissue perimeter, collagen fibers alignment while reducing percentage of structured areas and degree of collagen structuration. Additionally, the treatment reduced cell area of elongated fibroblasts under tension, without changes in the internal rounded cells devoid of tension. Fibroblast recruitment to tension areas was diminished, showing biomechanical behavior similar to control ECT. This treatment also lowered the gene and protein expression of key pro-fibrotic markers. For the first time, advanced biotechnology was employed to detect the detailed structure of tissue fibrosis reduction after administering CTPR390, representing a significant advancement toward clinical application for cardiac fibrosis treatment. Graphical


  • Open Access

    Fibroblast-derived extracellular vesicles as trackable efficient transporters of an experimental nanodrug with fibrotic heart and lung targeting

    by Jorge Ruizdel Rio, Gabriela Guedes, Danielle Novillo, Elena Lecue, Ana Palanca, Aitziber L. Cortajarena, Ana V. Villar

    The discovery of extracellular vesicles (EVs) as efficient exogenous biotransporters of therapeutic agents into cells across biological membranes is an exciting emerging field. Especially the potential of EVs as targeted delivery systems for diseases with selective treatments, such as fibrosis, whose treatment causes side effects in other organs not involved in the disease. Methods: In this study, we collected embryonic fibroblast-derived EVs from two different centrifugation fractions, 10 K g and 100 K g fractions from a NIH-3T3 cell line loaded with an experimental drug. Mice with fibrotic hearts and lungs were obtained by administration of angiotensin II. We generated fluorescent EVs and bioluminescent drug to observe their accumulation by colocalization of their signals in fibrotic heart and lung. The biodistribution of the drug in various organs was obtained by detecting the Au present in the drug nanostructure. Results: The drug-loaded EVs successfully reduced fibrosis in pathological fibroblasts in vitro, and modified the biodistribution of the experimental drug, enabling it to reach the target organs in vivo. We described the pre-analytical characteristics of EVs related to physical variables, culture and harvesting conditions, crucial for their in vivo application as nanotransporters using a previously validated protein-based antifibrotic drug. The results showed the colocalization of EVs and the experimental drug in vivo and ex vivo and the efficient reduction of fibrosis in vitro. This work demonstrates that 10K-EVs and 100K-EVs derived from fibroblasts can act as effective biotransporters for targeted drug delivery to profibrotic fibroblasts, lungs, or heart.


  • Profibrotic Role of Inducible Heat Shock Protein 90α Isoform in Systemic Sclerosis

    by Jorge RuizdelRio, Pedro Muñoz, Patricia Carreira, David Maestro, Jose L. Pablos, Ana Palanca, Jesus Merino, Anna Serrano-Mollar, Ramon Merino, Esther Tamayo, et al.

    Systemic sclerosis (SSc) is an autoimmune disease that affects skin and multiple internal organs. TGF-β, a central trigger of cutaneous fibrosis, activates fibroblasts with the involvement of the stress-inducible chaperone heat shock protein 90 isoform α (Hsp90α). Available evidence supports overexpression and secretion of Hsp90α as a feature in profibrotic pathological conditions. The aim of this work is to investigate the expression and function of Hsp90α in experimental models of skin fibrosis such as human fibroblasts, C57BL/6 mice, and in human SSc. For this purpose, we generated a new experimental model based on doxorubicin administration with improved characteristics with respect to the bleomycin model. We visualized disease progression in vivo by fluorescence imaging. In this work, we obtained Hsp90α mRNA overexpression in human skin fibroblasts, in bleomycin- and doxorubicin-induced mouse fibrotic skin, and in lungs of bleomycin- and doxorubicin-treated mice. Hsp90α-deficient mice showed significantly decreased skin thickness compared with wild-type mice in both animal models. In SSc patients, serum Hsp90α levels were increased in patients with lung involvement and in patients with the diffuse form of SSc (dSSc) compared with patients with the limited form of SSc. The serum Hsp90α levels of patients dSSc were correlated with the Rodnan score and the forced vital capacity variable. These results provide new supportive evidence of the contribution of the Hsp90α isoform in the development of skin fibrosis. In SSc, these results indicated that higher serum levels were associated with dSSc and lung fibrosis.


  • Open Access

    Correlative 3D cryo X-ray imaging reveals intracellular location and effect of designed antifibrotic protein–nanomaterial hybrids

    by J. Groen, A. Palanca, A. Aires, J. J. Conesa, D. Maestro, S. Rehbein, M. Harkiolaki, A. V. Villar, A. L. Cortajarena, E. Pereiro

    A novel 3D cryo correlative approach locates designed therapeutic protein–nanomaterial hybrids in whole cells with high specificity and resolution. Detection of treatment-induced morphological changes, crucial for pre-clinical studies, are revealed.


  • Open Access

    Sex-Specific Regulation of miR-29b in the Myocardium Under Pressure Overload is Associated with Differential Molecular, Structural and Functional Remodeling Patterns in Mice and Patients with Aortic Stenosis

    by Raquel García, Ana B. Salido-Medina, Aritz Gil, David Merino, Jenny Gómez, Ana V. Villar, Francisco González-Vílchez, María A. Hurlé, J. Francisco Nistal

    Pressure overload in patients with aortic stenosis (AS) induces an adverse remodeling of the left ventricle (LV) in a sex-specific manner. We assessed whether a sex-specific miR-29b dysregulation underlies this sex-biased remodeling pattern, as has been described in liver fibrosis. We studied mice with transverse aortic constriction (TAC) and patients with AS. miR-29b was determined in the LV (mice, patients) and plasma (patients). Expression of remodeling-related markers and histological fibrosis were determined in mouse LV. Echocardiographic morpho-functional parameters were evaluated at baseline and post-TAC in mice, and preoperatively and 1 year after aortic valve replacement (AVR) in patients with AS. In mice, miR-29b LV regulation was opposite in TAC-males (down-regulation) and TAC-females (up-regulation). The subsequent changes in miR-29b targets (collagens and GSK-3β) revealed a remodeling pattern that was more fibrotic in males but more hypertrophic in females. Both systolic and diastolic cardiac functions deteriorated more in TAC-females, thus suggesting a detrimental role of miR-29b in females, but was protective in the LV under pressure overload in males. Clinically, miR-29b in controls and patients with AS reproduced most of the sexually dimorphic features observed in mice. In women with AS, the preoperative plasma expression of miR-29b paralleled the severity of hypertrophy and was a significant negative predictor of reverse remodeling after AVR; therefore, it may have potential value as a prognostic biomarker.


  • Open Access

    Reduction of cardiac TGFβ-mediated profibrotic events by inhibition of Hsp90 with engineered protein

    by R.A. Cáceres, T. Chavez, D. Maestro, A.R. Palanca, P. Bolado, F. Madrazo, A. Aires, A.L. Cortajarena, A.V. Villar


  • Extracellular heat shock protein 90 binding to TGFβ receptor I participates in TGFβ-mediated collagen production in myocardial fibroblasts

    by Raquel García, David Merino, Jenny M. Gómez, J. Francisco Nistal, María A. Hurlé, Aitziber L. Cortajarena, Ana V. Villar